Key result
Beta and Delta spike antigens elicit higher neutralizing antibody activity than original reference strain vaccines.
Why the study?
Current vaccines may reduce severe disease from existing SARS-CoV-2 variants of concern, but variant-specific antigens may be needed to induce optimal immune responses and reduce infection.
Do variant-specific SARS-CoV-2 spike antigens elicit higher neutralizing antibody activity compared to reference strain vaccines?
Do variant-specific SARS-CoV-2 spike antigens elicit higher neutralizing antibody activity compared to reference strain vaccines?
Variant-specific antigens, whether in a mono- or multivalent vaccine, may be required to induce optimal immune responses against arising SARS-CoV-2 variants.
Answers are grounded in this paper and cite their sources.
Variant-matched antigens may improve neutralization breadth; leaves open whether updated vaccines alter clinical protection or transmission.
Using our strongly immunogenic SmT1 SARS-CoV-2 spike antigen platform, we developed antigens based on the Beta & Delta variants of concern (VOC). These antigens elicited higher neutralizing antibody activity to the corresponding variant than comparable vaccine formulations based on the original reference strain, while a multivalent vaccine generated cross-neutralizing activity in all three variants. This suggests that while current vaccines may be effective at reducing severe disease to existing VOC, variant-specific antigens, whether in a mono- or multivalent vaccine, may be required to induce optimal immune responses and reduce infection against arising variants.
No takes yet. Share an insight, caveat, or question.
Akache et al. (2022) studied SARS-CoV-2. Beta and Delta variant-specific SARS-CoV-2 spike antigens (SmT1v3-B, SmT1v3-D) vs. Reference strain spike antigen (SmT1v3-R) was evaluated on Neutralizing antibody activity against corresponding variants. SARS-CoV-2 spike antigens derived from Beta and Delta variants elicited higher neutralizing antibody activity to the corresponding variant than comparable vaccine formulations based on the original reference strain.
Synapse has enriched 10 related papers. Consider them for comparative context: